Clinical Trial Update: Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

This update concerns a Phase 1 study of UCART123v1.2 in relapsed/refractory acute myeloid leukemia, with the trial listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• UCART123v1.2

Snippet

Sponsor: Cellectis S.A. | Conditions: Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING